Will Ultragenyx/Kyowa Hypophosphatemia Data Support Uptake?
Ultragenyx and partner Kyowa Hakko Kirin said burosumab (KRN23) met the primary endpoint regarding phosphate levels in a Phase III study that enrolled adult X-linked hypophosphatemia patients, but small effects on two out of three secondary endpoints could impact the product's use.
You may also be interested in...
Keeping Track: A Fresh Wave Of Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Ultragenyx Gets Commercial Feet Wet With Mepsevii Launch In Sly Syndrome
Commercial opportunity for Mepsevii is small, but launch paves way for company's second product burosumab, following on its heels.
Keeping Track: FDA Hands Out Complete Responses, Expedited Pathway Designations
The latest US drug development news and highlights from our Performance Tracker.